Patent intelligence · US
US 6468959
Peroral dosage form for peptide containing medicaments, in particular insulin
Peroral dosage form for peptide containing medicaments, in particular insulin
Patent details — US 6468959
- Jurisdiction
- US
- Status
- expired
- Grant date
- Oct 22, 2002
- Expiration
- Oct 17, 2022
- Applicant
- ALFATEC-Pharm GmbH
- Claims
- 10
- CPC classes
- A61K, A61K38/28, A61K9/1658, A61K9/2063
Quick answer
US 6468959 (Peroral dosage form for peptide containing medicaments, in particular insulin) is held by ALFATEC-Pharm GmbH. Status: expired. Granted Oct 22, 2002. Expires Oct 17, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALFATEC-Pharm GmbH
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K38/28, A61K9/1658, A61K9/2063, A61K9/209, A61K9/2846
More from ALFATEC-Pharm GmbH
Related pharmaceutical patents in our USPTO index.
-
US 12419870
Compositions and methods for immune cell modulation in adoptive immunotherapies
granted -
US 12410403
Methods and compositions for inducing hematopoietic cell differentiation
granted -
US 12398373
Enhanced immune effector cells and use thereof
granted -
US 12385012
Methods and compositions for inducing hematopoietic cell differentiation
granted -
US 12281329
Compositions and methods for immune cell modulation in adoptive immunotherapies
granted -
US 12275955
Combining iPSC derived effector cell types for immunotherapy use
granted -
US 12264322
Minimal volume reprogramming of mononuclear cells
granted -
US 12247226
Cellular reprogramming using temporal and transient plasmid vector expression system
granted
Frequently asked questions
What is US patent 6468959?
US 6468959 (Peroral dosage form for peptide containing medicaments, in particular insulin) is held by ALFATEC-Pharm GmbH. Status: expired. Granted Oct 22, 2002. Expires Oct 17, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6468959?
ALFATEC-Pharm GmbH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 53 pharmaceutical patents for this assignee.
When does US 6468959 expire?
Our index shows an expiration date of Oct 17, 2022 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.